Evidence map›Paper›PMID 37257915›Full record

Trial reportBMJ open quality2023

Developing and delivering a hybrid Cardiac Rehabilitation Phase II exercise program during the COVID-19 pandemic: a quality improvement program.

Javier Loureiro Diaz, Liam David Foster, Praveen Jayaprabha Surendran, Prasobh Jacob, Omar Ibrahim, Poonam Gupta

Open access · goldAbstract readClinical Trial, Phase II
In one paragraph

Trial report in BMJ open quality, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Javier Loureiro DiazCardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar JLOUREIRODIAZ@GMAIL.COM.ORCID 0000-0003-1727-9135
Liam David FosterCardiac Rehabilitation Department, Cardiff and Vale University Health Board, Cardiff, UK.
Praveen Jayaprabha SurendranCardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0002-7417-3559
Prasobh JacobCardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0003-1153-6305
Omar IbrahimCardiac Rehabilitation Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Poonam GuptaPerformance Improvement Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0001-8737-8804
Hamad Medical Corporation · QACardiff and Vale University Health Board · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic resulted in the cessation of approximately 75% of cardiac rehabilitation (CR) programmes worldwide. In March 2020, CR phase II (CRP2) services were stopped in Qatar. Multiple studies had shown safety, effectiveness, reduced cost of delivery and improved participation with hybrid CR. A multidisciplinary team reviewed various alternative models for delivery and decided to implement a hybrid CRP2 exercise programme (HCRP2-EP) to ensure continuation of our patient care. Our aim was to enrol in the HCRP2-EP 70% of all eligible patients by 30 September 2020. Institute for Health Care Improvement's collaborative model was adopted. Multiple plan-do-study-act cycles were used to test change ideas. The outcomes of the project were analysed using standard run chart rules to detect the changes in outcomes over time. This project was implemented from March 2020, and the male patients enrolled between August 2020 and April 2021, with sustained monthly median enrolment above target of 70% throughout. As for our secondary outcome, 75.8% of the male patients who completed HCRP2-EP showed a meaningful change in peak exercise capacity of ≥10% (mean change 17%±6%). There were no major adverse events reported, and the median Patient Satisfaction Score was 96% well above the institutional target of 90%. This shows a well-designed quality improvement programme is an appropriate strategy for implementing HCRP2-EP in a clinical setting, and HCRP2-EP is a feasible, effective and safe intervention in eligible male patients with cardiovascular disease.

Indexed as

Cardiac RehabilitationCOVID-19Exercise TherapyHumansMalePandemicsQuality ImprovementCoronary DiseaseCOVID-19ExerciseHealthcare quality improvementRehabilitation

Identifiers

PMID37257915
PMCPMC10254689
OpenAlexW4378902964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.